Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Your search for TFRC returned no results
Showing 1601 to 1650 of 2486 results for term

  1. Adalimumab and dexamethasone for treating non-infectious uveitis (TA460)

    Evidence-based recommendations on adalimumab (Humira) and dexamethasone (Ozurdex) for treating non-infectious uveitis in adults.

  2. Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive minimal residual disease-negative B-cell precursor acute lymphoblastic leukaemia (TA1049)

    Evidence-based recommendations on blinatumomab (Blincyto) with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive minimal residual disease-negative B-cell precursor acute lymphoblastic leukaemia in adults.

  3. Self-sampling and self-testing:- How effective are self-sampling and self-testing in terms of accuracy of sampling, ability to reach different groups, test completion, receipt of results and subsequent care-seeking behaviour?

    Self-sampling and self-testing:- How effective are self-sampling and self-testing in terms of accuracy of sampling, ability to reach...

  4. Pemetrexed for the first-line treatment of non-small-cell lung cancer (TA181)

    Evidence-based recommendations on pemetrexed for untreated non-small-cell lung cancer in adults.

  5. Mental wellbeing and independence for older people (QS137)

    This quality standard covers interventions to maintain and improve the mental wellbeing and independence of people aged 65 or older, and how to identify those at risk of a decline. It describes high-quality care in priority areas for improvement. It does not cover the mental wellbeing and independence of people who live in a care home or attend one on a day-only basis.

  6. Ectopic pregnancy and miscarriage (QS69)

    This quality standard covers the diagnosis and initial management of ectopic pregnancy and miscarriage in women in their first trimester (up to 13 completed weeks of pregnancy). It includes assessment and diagnosis for women with suspected early pregnancy loss. It describes high-quality care in priority areas for improvement.

  7. clonoSEQ for minimal residual disease assessment in multiple myeloma, acute lymphoblastic leukaemia and chronic lymphocytic leukaemia (MIB278)

    NICE has developed a medtech innovation briefing (MIB) on clonoSEQ for minimal residual disease assessment in multiple myeloma, acute lymphoblastic leukaemia and chronic lymphocytic leukaemia .

  8. Rifaximin for preventing episodes of overt hepatic encephalopathy (TA337)

    Evidence-based recommendations on rifaximin (Targaxan) for preventing episodes of hepatic encephalopathy in adults.

  9. Type 1 diabetes in adults (QS208)

    This quality standard covers care and treatment for adults (aged 18 and over) with type 1 diabetes. It describes high-quality care in priority areas for improvement.

  10. Antenatal and postnatal mental health (QS115)

    This quality standard covers recognising, assessing and treating mental health problems in women planning, during or after pregnancy (up to a year after childbirth). It also covers the organisation of mental health services for women during and after pregnancy. It describes high-quality care in priority areas for improvement.

  11. UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia (HTG578)

    Evidence-based recommendations on UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia.

  12. Axonics sacral neuromodulation system for faecal incontinence (MIB259)

    NICE has developed a medtech innovation briefing (MIB) on Axonics sacral neuromodulation system for faecal incontinence .

  13. Anakinra for treating Still's disease (TA685)

    Evidence-based recommendations on anakinra (Kineret) for treating adult-onset Still’s disease and systemic juvenile idiopathic arthritis in people 8 months and older.

  14. What is the natural history of post-COVID-19 syndrome?

    Comes from guidance COVID-19 rapid guideline: managing the long-term effects of COVID-19 Number NG188 Date issued December

  15. Purchasing steps: direct awards

    A guide to the steps to follow when buying sole supplied titles from Lot 1 of our purchasing framework.

  16. Impetigo: antimicrobial prescribing (NG153)

    This guideline sets out an antimicrobial prescribing strategy for adults, young people and children aged 72 hours and over with impetigo. It aims to optimise antibiotic use and reduce antibiotic resistance.

  17. What symptoms do children, young people, pregnant women and older people with suspected post‑COVID‑19 syndrome present with?

    Comes from guidance COVID-19 rapid guideline: managing the long-term effects of COVID-19 Number NG188 Date issued December

  18. What is the clinical effectiveness of D-dimer and other blood tests and clinical features as prognostic markers of developing post‑COVID‑19 syndrome?

    Comes from guidance COVID-19 rapid guideline: managing the long-term effects of COVID-19 Number NG188 Date issued December

  19. What pathophysiological mechanism(s) underlie the most common presentations of post-COVID-19 syndrome? For example, generalised fatigue, breathlessness, and “brain fog”?

    Comes from guidance COVID-19 rapid guideline: managing the long-term effects of COVID-19 Number NG188 Date issued December

  20. Controlled drugs: safe use and management (NG46)

    This guideline covers systems and processes for using and managing controlled drugs safely in all NHS settings except care homes. It aims to improve working practices to comply with legislation and have robust governance arrangements. It also aims to reduce the safety risks associated with controlled drugs.

  21. Nivolumab in combination with ipilimumab for treating advanced melanoma (TA400)

    Evidence-based recommendations on nivolumab (Opdivo) with ipilimumab (Yervoy) for treating advanced (unresectable or metastatic) melanoma in adults.

  22. International collaboration provides new guidance on the use of surrogate endpoints in cost-effectiveness analysis

    Recommendations will help organisations that evaluate new drugs establish whether their use will result in longer-term benefits for patients

  23. Detecting, managing and monitoring haemostasis: viscoelastometric point‑of‑care testing (ROTEM, TEG and Sonoclot systems) (HTG348)

    Evidence-based recommendations on viscoelastometric point-of-care testing devices (the ROTEM, TEG and Sonoclot systems).

  24. Management of anaemia of CKD with concurrent illness: What is the optimal management (in terms of clinical and cost effectiveness) of anaemia of CKD in people who are receiving erythropoietic stimulating agents (ESAs) and have a significant concurrent acute infectious illness?

    anaemia of CKD with concurrent illness: What is the optimal management (in terms of clinical and cost effectiveness) of anaemia of CKD...

  25. Preventing suicide in community and custodial settings (NG105)

    This guideline covers ways to reduce suicide and help people bereaved or affected by suicides. It aims to:

  26. Health Technology Assessment Innovation Laboratory (HTA Lab)

    NICE's HTA Lab enables us to develop creative solutions to complex problems in health technology assessment.

  27. Negative pressure wound therapy for the open abdomen (HTG321)

    Evidence-based recommendations on negative pressure wound therapy for the open abdomen. This involves using a small pump to remove infected material, stop fluid escaping and help the wound heal.

  28. Renal and ureteric stones (QS195)

    This quality standard covers assessing and managing renal and ureteric stones in children, young people and adults. It describes high-quality care in priority areas for improvement.

  29. Food allergy (QS118)

    This quality standard covers diagnosing, assessing and managing food allergy in children and young people (under 19) and adults. It describes high-quality care in priority areas for improvement.

  30. Transition between inpatient mental health settings and community or care home settings (QS159)

    This quality standard covers transitions for children, young people and adults between mental health hospitals and their own homes, care homes or other community settings. It includes the period before, during and after a person is admitted to, and discharged from, a mental health hospital. It describes high-quality care in priority areas for improvement.

  31. Irritable bowel syndrome in adults (QS114)

    This quality standard covers diagnosing and managing irritable bowel syndrome in adults. It describes high-quality care in priority areas for improvement.

  32. Head and neck cancer (QS146)

    This quality standard covers assessing, diagnosing and managing head and neck cancer, including cancer of the upper aerodigestive tract in people aged 16 or over. It describes high-quality care in priority areas for improvement.

  33. Technology appraisal committees

    Membership details, terms of reference, future meeting dates and past meeting minutes for our 4 technology appraisal committees.

  34. Technology appraisal committees

    Membership details, terms of reference, future meeting dates and past meeting minutes for our 4 technology appraisal committees.

  35. Further research should be in the form of randomised controlled trials or registries. It should report:

    dysfunction details of the procedure, including the device used short- and long-term outcomes, including patient-reported outcomes....

  36. Jaundice in newborn babies under 28 days (QS57)

    This quality standard covers recognising and managing jaundice in newborn babies (neonatal jaundice), from birth to 28 days, in primary care (including community care) and secondary care. It describes high-quality care in priority areas for improvement.

  37. NICE encourages research into endovascular stentgrafting of popliteal aneurysms and may review this procedure on publication of further evidence.

    concerns. Evidence on efficacy is inadequate because it is limited to the short-term. Therefore this procedure should only be used with...

  38. Evidence on the safety and efficacy of midcarpal hemiarthroplasty for wrist arthritis is inadequate in quantity and quality. Therefore, this procedure should only be used in the context of  research .

    patient-reported outcome measures and the need for revision in the longer term (at least 5 years). Source guidance details Comes from...

  39. Evidence on the safety and efficacy of high-intensity focused ultrasound for glaucoma is inadequate in quality and quantity. Therefore, this procedure should only be used in the context of  research .

    procedure with standard therapies and should report safety events and long-term outcomes. NICE may update the guidance on publication of...

  40. Percutaneous transluminal renal sympathetic denervation for resistant hypertension should only be used with special arrangements for clinical governance, consent, and audit or research. Find out what special arrangements mean on the NICE interventional procedures guidance page.

    data. It should report details of patient selection, technique used and long-term outcomes. Source guidance details Comes from guidance...

  41. Current evidence on the safety and efficacy of bronchoscopic thermal vapour ablation for upper-lobe emphysema is inadequate in quantity and quality. Therefore the procedure should only be used in the context of  research .

    Further research should evaluate safety and efficacy in the short and long term and include details of patient selection. NICE may...

  42. Duration of thyroid stimulating hormone suppression: For people with differentiated thyroid cancer who have had surgery and radioactive iodine (RAI), what is the optimal duration of thyroid stimulating hormone suppression?

    made this recommendation for research, see the rationale section on long-term duration of TSH suppression. Full details of the evidence...

  43. The social care guidance manual (PMG10)

    This manual explains how NICE develops and updates social care guidance. It provides advice on the technical aspects of guidance development and the methods used

  44. Artificial intelligence (AI) technologies to help detect or characterise colorectal polyps (HTG773)

    Evidence-based recommendations on artificial intelligence technologies to help detect or characterise colorectal polyps.

  45. Urinary incontinence and pelvic organ prolapse in women. Patient decision aid on surgery for uterine prolapse

    any of the others for treating uterine prolapse, especially in the longer term. Prolapse seems to be more likely to come back after...

  46. Liver disease (QS152)

    This quality standard covers identifying, assessing and managing chronic liver disease in children, young people and adults, and cirrhosis in young people and adults. It describes high-quality care in priority areas for improvement.